Paroxetin-Augmentation mit Risperidon bei therapieresistenter Depression

Zusammenfassung

Bei einer 71-jährigen Patientin wurde eine schwere therapieresistente depressive Episode ohne psychotische Symptome erfolgreich mit einer Kombination aus Paroxetin und Risperidon behandelt. Zuvor hatte eine Vielzahl von Antidepressiva die seit mehr als zehn Jahren rezidivierenden depressiven Episoden nicht oder nur unzureichend beeinflussen können.

Paroxetine Augmentation with Risperidone in Therapy-Resistant Depression

In a 71 years-old patient, a severe therapy-resistant depressive episode without psychotic symptoms was successfully treated by a combination of paroxetine and risperidone. Previously, several different antidepressants were not effective in ameliorating the depressive symptoms which occurred repeatedly over a period of more than ten years.

Literatur

• 1 Fava M. New approaches to the treatment of refractory depression.  J Clin Psychiatry. 2000;  61, Suppl 1 26-32
• 2 Walters G, Reynolds C F, Mulsant B H, Pollock B G. Continuation and maintenance pharmacotherapy in geriatric depression: an open-trial comparison of paroxetine and nortriptyline in patients older than 70 years.  J Clin Psychiatry. 1999;  60, Suppl 20 21-25
• 3 Peuskens J, Van Baelen B, De Smedt C, Lemmens P. Effects of risperidone on affective symptoms in patients with schizophrenia.  Int Clin Psychopharmacol. 2000;  15 343-349
• 4 Ostroff R B, Nelson J C. Risperidone augmentation of selective serotonin reuptake inhibitors in major depression.  J Clin Psychiatry. 1999;  60 256-258
• 5 Nelson J C. Augmentation strategies in depression 2000.  J Clin Psychiatry. 2000;  61, Suppl 2 13-19
• 6 Souery D, Amsterdam J, de Montigny C, Lecrubier Y, Montgomery S, Lipp O, Racagni G, Zohar J, Mendlewicz J. Treatment resistant depression: Methodological overview and operational criteria.  Eur Neuropsychopharmacol. 1999;  9 83-91
• 7 Wolfersdorf M, König F, Straub R. Pharmacotherapy of delusional depression: Experience with combinations of antidepressants with the neuroleptics zotepine and haloperidol.  Neuropsychobiol. 1994;  29 189-193
• 8 Zarate C A, Narendran R, Tohen M, Greaney J J, Berman A, Pike S, Madrid A. Clinical predictors of acute response with olanzapine in psychotic mood disorders.  J Clin Psychiatry. 1998;  59 24-28
• 9 O'Connor M, Silver H. Adding risperidone to selective serotonin reuptake inhibitor improves chronic depression.  J Clin Psychopharmacol. 1998;  18 89-91
• 10 Knable M B, Heinz A, Raedler T, Weinberger D R. Extrapyramidal side effects with risperidone and haloperidol at comparable D2 receptor occupancy levels.  Psychiatry Res. 1997;  75 91-101
• 11 Keck P E, McElroy S L, Strakowski S M, Soutullo C A. Antipsychotics in the treatment of mood disorders and risk of tardive dyskinesia.  J Clin Psychiatry. 2000;  61, Suppl 4 33-38
• 12 Sechi G, Agnetti V, Masuri R, Deiana G A, Pugliatti M, Paulus K S, Rosati G. Risperidone, neuroleptic malignant syndrome and probable dementia with Lewy bodies.  Prog Neuropsychopharmacol Biol Psychiatry. 2000;  24 1043-1051
• 13 Aubry J M, Simon A E, Bertschy G. Possible induction of mania and hypomania by olanzapine or risperidone: a critical review of reported cases.  J Clin Psychiatry. 2000;  61 649-655